Clinical Trials Directory

Trials / Terminated

TerminatedNCT01927484

Hand OA AND Methotrexate Use

Methotrexate in Hand Osteoarthritis

Status
Terminated
Phase
N/A
Study type
Interventional
Enrollment
2 (actual)
Sponsor
University of Alexandria · Academic / Other
Sex
All
Age
60 Years
Healthy volunteers
Not accepted

Summary

Osteoarthritis (OA) is a common disabling condition, for which no effective therapy currently exists. Synovitis has been demonstrated in hand OA imaging. Synovial inflammation due to the release of cytokines is an important cause of pain. Methotrexate (MTX) helps to decrease synovitis in many inflammatory joint diseases, particularly rheumatoid arthritis. The aim of the present study is to assess the efficacy of MTX in decreasing pain and inflammation in symptomatic hand OA. Methods: One hundred and twenty patients with American College of Rheumatology (ACR) clinical and radiographic criteria of primary knee OA with hand pain, \[\>4 on the 24-hour average pain severity scale (0-10) using mean of daily ratings from week preceding randomization\] for \> 14 days/month during 3 consecutive months preceding enrollment will be included in this randomized double-blind placebo-controlled trial. Patients meeting the eligibility criteria were randomized in a 1:1 ratio to receive either 25mg/week oral MTX (n=60) or placebo (n=60) together with their usual therapy provided the dosages were kept constant for 28 weeks. Pain will be assessed using the Visual Analogue pain Scale, (VAS, 0-100 mm). Functional assessment will be performed using the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) and Activities of daily living (ADL) scores. Alterations in dosage of analgesic/NSAID drugs used will be recorded. Safety and tolerability will also be assessed. Synovitis will be detected by ultrasound imaging.

Conditions

Interventions

TypeNameDescription
DRUG25 mg/week oral methotrexate tabletsactive oral methotrexate drug
DRUG25mg/week oral placebo tabletsplacebo comparator oral drug

Timeline

Start date
2020-03-07
Primary completion
2020-03-11
Completion
2020-03-11
First posted
2013-08-22
Last updated
2020-08-12

Locations

1 site across 1 country: Egypt

Source: ClinicalTrials.gov record NCT01927484. Inclusion in this directory is not an endorsement.